ConductScience.org, home

Comparison · NCT05049616-90fbba99

Hctz/Lisinopril vs Extended release nifedipine: Number of Participants Who Received Additional Antihypertensive During Admission

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Hctz/Lisinopril vs Extended release nifedipine: Number of Participants Who Received Additional Antihypertensive During Admission. Trial comparisons, record NCT05049616-90fbba99. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT05049616-90fbba99

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.1940.09190.363wilson
Risk in group 20.1390.06080.287wilson
Risk difference, group 1 minus group 20.0547-0.1250.241newcombe hybrid score
Risk ratio, group 1 over group 21.390.4714.13log
Odds ratio, group 1 over group 21.490.4065.45log
Number needed to treat, for one more participant with the outcome on Hctz/Lisinopril than on Extended release nifedipine18.3from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Hctz/Lisinopril
Hctz/Lisinopril for postpartum management of hypertension. either a combined pill of ACE inhibitors and diuretics (Hydrochlorothiazide/Lisinopril)~ACE Inhibitors and Diuretics: Hctz/Lisinopril (brand name: Zestoretic)
631OG000
Group 2Extended release nifedipinecalcium channel blocker (Nifedipine~NIFEdipine ER: Extended release nifedipine536OG001

Outcome

Type
SECONDARY
Title
Number of Participants Who Received Additional Antihypertensive During Admission
Description
number of participants who received additional antihypertensive during admission, at 7-10 days postpartum.
Time frame
7-10 days postpartum
Population

Source ClinicalTrials.gov

Trial

Title
Oral Combined Hydrochlorothiazide/Lisinopril Versus Oral Nifedipine for Postpartum Hypertension
NCT number
NCT05049616
Phases
PHASE4
Conditions
Hypertension in Pregnancy, Postpartum Preeclampsia
Interventions
ACE Inhibitors and Diuretics, NIFEdipine ER
Lead sponsor
The University of Texas Health Science Center, Houston
Results first posted
2023-08-14

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT05049616-90fbba99